PTC Therapeutics (PTCT) Misses Q1 EPS by 3c

PTC Therapeutics (NASDAQ: PTCT) reported Q1 EPS of ($0.46), $0.03 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $56.1 million versus the consensus estimate of $56.72 million.

GUIDANCE:

PTC Therapeutics sees Q2 2018 net product revenue of $260-295 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance
• Bill.com (BILL) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 Guidance
• Deere shares climb as fiscal Q3 earnings and revenue top estimates